Antidiabetic therapy at admission and survival in diabetic patients with acute myocardial infarction

HIGHLIGHTS: Anti-diabetic drugs used at admission in myocardial infarction patients were studied. 195 admissions corresponding to different patients were under analysis. No difference in survival was seen in patients using or not using DPP-4 inhibitors. INTRODUCTION: Diabetes mellitus is frequently associated to cardiovascular disease. We aimed at studying the relations between anti-diabetic drugs in use at admission by diabetic patients with acute myocardial infarction and survival after a period of at least 36 and up to 52 months after admission. METHODS: Retrospective study based on electronic records. Data from a total number of 195 admissions corresponding to different patients were under analysis. RESULTS: Kaplan–Meier analysis, as well as Cox analysis, failed to show a difference in survival associated to the use of DPP-4 inhibitors (n = 35 patients). A non-significant trend toward increased survival was seen with metformin (n = 92 patients), and in the opposite direction with both insulin (n = 51 patients) and sulfonylureas (n = 51 patients). CONCLUSIONS: The use of DPP-4 inhibitors at admission, in patients with Diabetes mellitus admitted for acute myocardial infarction, was not associated to a different survival after no less than 36 months and up to 52 months after admission.